TMCnet - World's Largest Communications and Technology Community



Research and Markets: OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017
[February 06, 2014]

Research and Markets: OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2017" report to their offering.

The bladder cancer market in the 6MM to grow modestly from $239.3m in 2012 to $297.5m in 2017, at a CAGR of 4%.

Despite the Launch of Spectrum (News - Alert) Pharmaceuticals' EOquin, Nominal Growth in US and EU Bladder Cancer Market Is Expected from 2012 to 2017

The authors estimates the bladder cancer market in the US and 5EU (France, Germany, Italy, Spain, and UK) in 2012 to be valued at $239.3m. This market is defined as the sales of branded drugs, including Valstar (US only) and Javlor (Europe only), and major generics regimens across both markets. Predominantly due to the higher price of drugs, the majority of sales were generated in the US market, $139.m (58%), with EU sales estimated to be $99.8m (42%).

By the end of the study period in 2017, The authors forecasts global sales in the bladder cancer market to increase to $297.5m, at a compound annual growth rate (CAGR) of 4%. The majority of sales at this point will still come from the US, with $181.1m (61%), with its market share increasing marginally from 58% in 2012 to 61% by the end of the forecast period. Overall, The authors expects an increase in market size primarily due to a forecast increase in number of incident cases across the study period in the 6MM and the entrance of EOquin into the market during the forecast period.

The emergence of Spectrum Pharmaceuticals' EOquin, the only product in the pipeline to enter the market during the forecast period, will also have a small incremental effect on the bladder cancer market. Global sales for EOquin will account for $13.2m in its launch year, 2016, and $26.1m in 2017, accounting for 8.8% of sales in that year.

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Disease Overview

4 Epidemiology

4.1 Disease Background

4.2 Risk Factors and Comorbidities

4.3 Global Trends

4.4 Forecast Methodology

4.5 Epidemiological Forecast for Bladder Cancer (2012-2022)

4.6 Discussion

5 Current Treatment Options

5.1 Overview

5.2 Product Profiles - Major Brands

6 Unmet Needs Assessment and Opportunity Analysis

6.1 Overview

6.2 Unmet Needs Analysis

6.3 Opportunity Analysis

7 R&D Strategies

7.1 Overview

7.2 Clinical Trial Design

8 Pipeline Assessment

8.1 Overview

8.2 Promising Drugs in Clinical Development

8.3 Innovative Early-Stage Approaches

9 Pipeline Valuation Analysis

10 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy